Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2011

View Archived Issues

Immunocytokine C2-2b-2b targets IFN-alpha-2b to tumor sites with enhanced antiproliferative activity

FDA approves Nexium I.V. for pediatric and adolescent patients with GERD

NanoViricides reports new data on FluCide candidates in model of lethal H1N1 influenza

12D03 targets mutant epidermal growth factor receptor and has antitumor activity

K-115 is safe and reduces intraocular pressure in clinical settings

Humanized MAb NEO-201 shows preclinical promise for treatment of solid tumors

New frizzled SMO receptor antagonist SEN-450 inhibits tumor growth in vivo

New GPR119 receptor modulators designed at IRM

Jenrin Discovery presents new cannabinoid CB1 receptor antagonists/inverse agonists

Novel antibacterial aminoglycoside analogues prepared by Achaogen

Karo Bio synthesizes new estrogen receptor-beta ligands

Methamphetamine-targeted dendribodies show no toxicity in vitro

Allergan discloses novel lysophospholipid S1P2 receptor antagonists

XOMA-3AB, a triple-antibody product against botulinum neurotoxin type A, enters phase I

Cell Therapeutics to resubmit NDA for pixantrone following review by FDA

Global Health Ventures advances with plans to conduct U.S. clinical trials of X-Excite

Biovista and Novartis enter research collaboration

Affinium Pharmaceuticals reports phase I data on AFN-1252

FDA grants priority review to Seattle Genetics' brentuximab vedotin BLAs

Seattle BioMed receives grant to identify biomarkers for malaria vaccine design

Synairgen's IFN-beta shows in vitro efficacy against bird flu

Lantheus provides FDA advisory committees with safety data for ultrasound contrast agent Definity

Teva Pharma to acquire Cephalon

Health Canada approves Vimovo

First patients with heart failure dosed in Nile Therapeutics' phase I cenderitide study

Otsuka Pharma begins phase I OPB-51602 study in hematological malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...